Citrullinated and homocitrullinated low- density lipoprotein in rheumatoid arthritis

References

• Widdifield J, Paterson JM, Huang A, Bernatsky S. Causes of death in rheumatoid arthritis: how do they compare to the general population? Arthritis Care Res (Hoboken) 2018;70:1748–55.
   PubMed Web of Science ®Google Scholar
• Hedström AK, Klareskog L, Alfredsson L. Interplay between obesity and smoking with regard to RA risk. RMD Open 2019;5:e000856.
   PubMed Web of Science ®Google Scholar
• Skeoch S, Bruce IN. Atherosclerosis in rheumatoid arthritis: is it all about inflammation? Nat Rev Rheumatol 2015;11:390–400.
   PubMed Web of Science ®Google Scholar
• Del Rincon ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.
   PubMed Web of Science ®Google Scholar
• Myasoedova E, Crowson CS, Kremers HM, Roger VL, Fitz-Gibbon PD, Therneau TM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis 2011;70:482–7.
   PubMed Web of Science ®Google Scholar
• Escalante A, Haas RW, Del Rincon I. Paradoxical effect of body mass index on survival in rheumatoid arthritis: role of comorbidity and systemic inflammation. Arch Intern Med 2005;165:1624–9.
   PubMedGoogle Scholar
• Derksen VFAM, Huizinga TWJ, van der Woude D. The role of autoantibodies in the pathophysiology of rheumatoid arthritis. Semin Immunopathol 2017;39:437–46.
   PubMed Web of Science ®Google Scholar
• Demoruelle MK, Wilson TM, Deane KD. Lung inflammation in the pathogenesis of rheumatoid arthritis. Immunol Rev 2020;294:124–32.
   PubMed Web of Science ®Google Scholar
• Scinocca M, Bell DA, Racapé M, Joseph R, Shaw G, McCormick JK, et al. Antihomocitrullinated fibrinogen antibodies are specific to rheumatoid arthritis and frequently bind citrullinated proteins/peptides. J Rheumatol 2014;41:270–9.
   PubMed Web of Science ®Google Scholar
• Shi J, van Veelen PA, Mahler M, Janssen GM, Drijfhout JW, Huizinga TW, et al. Carbamylation and antibodies against carbamylated proteins in autoimmunity and other pathologies. Autoimmun Rev 2014;13:225–30.
   PubMed Web of Science ®Google Scholar
• Lac P, Racapé M, Barra L, Bell DA, Cairns E. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis. J Rheumatol 2018;45:302–9.
   PubMed Web of Science ®Google Scholar
• Wang Z, Nicholls SJ, Rodriguez ER, Kummu O, Horkko S, Barnard J, et al. Protein carbamylation links inflammation, smoking, uremia and atherogenesis. Nat Med 2007;13:1176–84.
   PubMed Web of Science ®Google Scholar
• Verheul MK, Yee A, Seaman A, Janssen GM, van Veelen PA, Drijfhout JW, et al. Identification of carbamylated alpha 1 anti-trypsin (A1AT) as an antigenic target of anti-CarP antibodies in patients with rheumatoid arthritis. J Autoimmun 2017;80:77–84.
   PubMed Web of Science ®Google Scholar
• Sohrabian A, Mathsson-Alm L, Hansson M, Knight A, Lysholm J, Cornillet M, et al. Number of individual ACPA reactivities in synovial fluid immune complexes, but not serum anti-CCP2 levels, associate with inflammation and joint destruction in rheumatoid arthritis. Ann Rheum Dis 2018;77:1345–53.
   PubMed Web of Science ®Google Scholar
• Sokolove J, Brennan MJ, Sharpe O, Lahey LJ, Kao AH, Krishnan E, et al. Brief report: citrullination within the atherosclerotic plaque: a potential target for the anti-citrullinated protein antibody response in rheumatoid arthritis. Arthritis Rheum 2013;65:1719–24.
   PubMed Web of Science ®Google Scholar
• Chistiakov DA, Bobryshev YV, Orekhov AN. Macrophage-mediated cholesterol handling in atherosclerosis. J Cell Mol Med 2016;20:17–28.
   PubMed Web of Science ®Google Scholar
• Burut DF, Karim Y, Ferns GA. The role of immune complexes in atherogenesis. Angiology 2010;61:679–89.
   PubMed Web of Science ®Google Scholar
• Sherer Y, Gerli R, Vaudo G, Schillaci G, Gilburd B, Giordano A, et al. Prevalence of antiphospholipid and antioxidized low-density lipoprotein antibodies in rheumatoid arthritis. Ann N Y Acad Sci 2005;1051:299–303.
   PubMed Web of Science ®Google Scholar
• Apostolov EO, Ok E, Burns S, Nawaz S, Savenka A, Shah S, et al. Carbamylated-oxidized LDL: proatherosclerotic effects on endothelial cells and macrophages. J Atheroscler Thromb 2013;20:878–92.
   PubMed Web of Science ®Google Scholar
• Kay J, Upchurch KS. ACR/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology(Oxford) 2012;51(Suppl 6):vi5–9.
   PubMed Web of Science ®Google Scholar
• Bykerk VP, Akhavan P, Hazlewood GS, Schieir O, Dooley A, Haraoui B, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012;39:1559–82.
   PubMed Web of Science ®Google Scholar
• Evans AL, Blackburn JWD, Yin C, Heit B. Quantitative efferocytosis assays. Methods Mol Biol 2017;1519:25–41.
   PubMedGoogle Scholar
• Yancey PG, Miles S, Schwegel J, Jerome WG. Uptake and trafficking of mildly oxidized LDL and acetylated LDL in THP-1 cells does not explain the differences in lysosomal metabolism of these two lipoproteins. Microsc Microanal 2002;8:81–93.
   PubMed Web of Science ®Google Scholar
• Prassl R, Laggner P. Molecular structure of low density lipoprotein: current status and future challenges. Eur Biophys J 2009;38:145–58.
   PubMed Web of Science ®Google Scholar
• Chen SH, Yang CY, Chen PF, Setzer D, Tanimura M, Li WH, et al. The complete cDNA and amino acid sequence of human apolipoprotein B-100. J Biol Chem 1986;261:12918–21.
   PubMed Web of Science ®Google Scholar
• Hörkkö S, Huttunen K, Kervinen K, Kesäniemi YA. Decreased clearance of uraemic and mildly carbamylated low-density lipoprotein. Eur J Clin Invest 1994;24:105–13.
   PubMed Web of Science ®Google Scholar
• Lugli EB, Correia RE, Fischer R, Lundberg K, Bracke KR, Montgomery AB, et al. Expression of citrulline and homocitrulline residues in the lungs of non-smokers and smokers: implications for autoimmunity in rheumatoid arthritis. Arthritis Res Ther 2015;17:9.
   PubMed Web of Science ®Google Scholar
• Gonen B, Cole T, Hahm KS. The interaction of carbamylated low-density lipoprotein with cultured cells. Studies with human fibroblasts, rat peritoneal macrophages and human monocyte-derived macrophages. Biochim Biophys Acta 1983;754:201–7.
   PubMed Web of Science ®Google Scholar
• Apostolov EO, Shah SV, Ok E, Basnakian AG. Quantification of carbamylated LDL in human sera by a new sandwich ELISA. Clin Chem 2005;51:719–28.
   PubMed Web of Science ®Google Scholar
• Verbrugge FH, Tang WH, Hazen SL. Protein carbamylation and cardiovascular disease. Kidney Int 2015;88:474–8.
   PubMed Web of Science ®Google Scholar
• Tanigaki K, Sundgren N, Khera A, Vongpatanasin W, Mineo C, Shaul PW. Fcγ receptors and ligands and cardiovascular disease. Circ Res 2015;116:368–84.
   PubMed Web of Science ®Google Scholar
• Lopes-Virella MF, Virella G. Modified LDL immune complexes and cardiovascular disease. Curr Med Chem 2019;26:1680–92.
   PubMed Web of Science ®Google Scholar
• Fernández-Friera L, Ibáñez B, Fuster V. Imaging subclinical atherosclerosis: is it ready for prime time? A review. J Cardiovasc Transl Res 2014;7:623–34.
   PubMed Web of Science ®Google Scholar
• Reed E, Jiang X, Kharlamova N, Ytterberg AJ, Catrina AI, Israelsson L, et al. Antibodies to carbamylated α-enolase epitopes in rheumatoid arthritis also bind citrullinated epitopes and are largely indistinct from anti-citrullinated protein antibodies. Arthritis Res Ther 2016;18:96.
   PubMed Web of Science ®Google Scholar
• Kummu O, Turunen SP, Prus P, Lehtimäki J, Veneskoski M, Wang C, et al. Human monoclonal Fab and human plasma antibodies to carbamyl-epitopes cross-react with malondialdehyde-adducts. Immunology 2014;141:416–30.
   PubMed Web of Science ®Google Scholar
• Spinelli FR, Pecani A, Ciciarello F, Colasanti T, Di Franco M, Miranda F, et al. Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients. BMC Musculoskelet Disord 2017;18:214.
   PubMed Web of Science ®Google Scholar
• Cambridge G, Acharya J, Cooper JA, Edwards JC, Humphries SE. Antibodies to citrullinated peptides and risk of coronary heart disease. Atherosclerosis 2013;228:243–6.
   PubMed Web of Science ®Google Scholar
• Lopes-Virella MF, Virella G. Pathogenic role of modified LDL antibodies and immune complexes in atherosclerosis. J Atheroscler Thromb 2013;20:743–54.
   PubMed Web of Science ®Google Scholar